Literature DB >> 25303781

[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].

José L Gorriz1, Félix Gutiérrez2, Joan C Trullàs3, Piedad Arazo4, Jose R Arribas5, Guillermina Barril6, Miguel Cervero7, Frederic Cofán8, Pere Domingo9, Vicente Estrada10, Xavier Fulladosa11, María J Galindo12, Sílvia Gràcia13, José A Iribarren14, Hernando Knobel15, José López-Aldeguer16, Fernando Lozano17, Alberto Martínez-Castelao11, Esteban Martínez8, Maria A Mazuecos18, Celia Miralles19, Rosario Montañés12, Eugenia Negredo20, Rosario Palacios21, María J Pérez-Elías22, Joaquín Portilla23, Manuel Praga24, Carlos Quereda21, Antonio Rivero25, Juan M Santamaría26, José Sanz27, Jesús Sanz6, José M Miró8.   

Abstract

The aim of this article is to update the 2010 recommendations on the evaluation and management of renal disease in human immunodeficiency virus (HIV)-infected patients. Renal function should be monitored in all HIV-infected patients. The basic renal work-up should include measurements of serum creatinine, estimated glomerular filtration rate by CKD-EPI, urine protein-to-creatinine ratio, and urinary sediment. Tubular function tests should include determination of serum phosphate levels and urine dipstick for glycosuria. In the absence of abnormal values, renal screening should be performed annually. In patients treated with tenofovir, or with risk factors for chronic kidney disease (CKD), more frequent renal screening is recommended. In order to prevent disease progression, potentially nephrotoxic antiretroviral drugs are not recommended in patients with CKD or risk factors for CKD. The document provides indications for renal biopsy and advises on the optimal time for referral of a patient to the nephrologist. The indications for and evaluation and management of dialysis and renal transplantation are also addressed.
Copyright © 2014 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  AIDS; Antiretroviral therapy; Chronic kidney disease; Enfermedad renal crónica; Fármacos antirretrovirales; Human immunodeficiency virus; Insuficiencia renal; Renal failure; Renal toxicity; Renal transplantation; Sida; Tenofovir; Toxicidad renal; Trasplante renal; Virus de la inmunodeficiencia humana

Mesh:

Substances:

Year:  2014        PMID: 25303781     DOI: 10.1016/j.eimc.2014.09.002

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  1 in total

1.  Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity.

Authors:  Anna Bonjoch; Patricia Echeverría; Núria Perez-Alvarez; Jordi Puig; Carla Estany; Bonaventura Clotet; Eugènia Negredo
Journal:  Biomed Res Int       Date:  2016-12-18       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.